AGBL1: A Protein Involved in A Wide Range of Physiological Processes

Target Name: AGBL1

NCBI ID: G123624

AGBL1

AGBL1: A Protein Involved in A Wide Range of Physiological Processes

AGBL carboxypeptidase 1 (AGBL1) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and muscles. It is a member of the family of carboxypeptidases, which are a group of enzymes that belong to the superfamily of ATP-dependent proteinases (APDases). These enzymes catalyze the hydrolysis of carboxyl groups on peptides, which is a critical step in the breakdown of many proteins and nucleic acids.

AGBL1 is involved in a wide range of physiological processes in the body, including the regulation of protein homeostasis, cell signaling, and inflammation. It has been implicated in a number of diseases, including diabetes, obesity, and neurodegenerative disorders. In addition, it is a potential drug target for a variety of therapeutic approaches, including inhibitors of carboxypeptidase activity and modulators of its expression.

One of the key functions of AGBL1 is its role in the regulation of protein homeostasis. This is a critical process that involves the constant surveillance and maintenance of the ratio of protein to protein precursors in the cell. AGBL1 is involved in the breakdown of many of the proteins that are synthesized in the cell and are either used for maintenance or recycled. This helps to maintain the delicate balance of protein synthesis and degradation that is necessary for the survival of the cell.

In addition to its role in protein homeostasis, AGBL1 is also involved in the regulation of cell signaling. Many signaling pathways rely on the activation and regulation of protein kinases, which are critical for the growth, survival, and differentiation of cells. AGBL1 has been shown to be involved in the regulation of several key signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the JAK/STAT signaling pathway.

AGBL1 has also been implicated in the development and progression of a number of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of neurons and the development of neurofibrillary tangles in the brain. In addition , AGBL1 has been shown to be involved in the regulation of the production and degradation of neurotransmitters, which are critical for the function of neuronal cells.

In addition to its involvement in neurodegenerative disorders, AGBL1 is also a potential drug target for a variety of other therapeutic approaches. For example, inhibitors of AGBL1 have been shown to be effective in treating a variety of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease . In addition, modulators of AGBL1 expression have been shown to be effective in reducing the production of neurotransmitters, which may be a useful approach in the treatment of psychiatric and neurological disorders.

In conclusion, AGBL1 is a complex and highly versatile protein that is involved in a wide range of physiological processes in the body. It is a potential drug target for the treatment of a variety of neurodegenerative disorders, as well as other diseases. Further research is needed to fully understand the role of AGBL1 in the regulation of protein homeostasis, cell signaling, and inflammation, as well as its potential as a therapeutic approach.

Protein Name: AGBL Carboxypeptidase 1

Functions: Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins. Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of tubulin protein. Specifically cleaves tubulin long-side-chains, while it is not able to remove the branching point glutamate. Also catalyzes the removal of polyglutamate residues from the carboxy-terminus of non-tubulin proteins such as MYLK

The "AGBL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGBL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets